1-10 of 10
Suresh Bobba
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Rami S. Komrokji, Maria Diez-Campelo, Lynette C.Y. Chee, Thomas Cluzeau, Amy E. DeZern, Pierre Fenaux, Guillermo Garcia-Manero, Aristoteles Giagounidis, Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Mikkael A. Sekeres, Amer M. Zeidan, Rena Buckstein, Miranda Ross, Ying Jiang, Suresh Bobba, Montagu Hankin, Chris Materna, Christine Graham, Sanjay Thamake, Christopher Rovaldi, Dena Grayson, Jen L. Salstrom
Journal: Blood
Blood (2024) 144 (Supplement 1): 3228.1.
https://doi.org/10.1182/blood-2024-200797
Published: 2024
Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Claire Harrison, Lynette C.Y. Chee, Timothy Devos, Maria Laura Fox, Alessandra Iurlo, Francesca Palandri, David M Ross, Shuhying Tan, Alessandro Maria Vannucchi, Marielle Wondergem, Michael Pace, Hongying Wang, Ming Yang, Ying Jiang, Suresh Bobba, Montagu Hankin, Chris Materna, Christine Graham, Sanjay Thamake, Christopher Rovaldi, Dena Grayson, Jen L. Salstrom
Journal: Blood
Blood (2024) 144 (Supplement 1): 997.
https://doi.org/10.1182/blood-2024-201729
Published: 2024
Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Aristoteles Giagounidis, Monteserrat Arnan, Lynette C.Y. Chee, Thomas Cluzeau, Maria Diez-Campelo, Devendra Hiwase, David M Ross, Mikkael A. Sekeres, Shuhying Tan, David Valcarcel, Rena Buckstein, Bhavna Patel-Shah, Ming Yang, Ying Jiang, Jiani Yin, Suresh Bobba, Montagu Hankin, Chris Materna, Christine Graham, Sanjay Thamake, Christopher Rovaldi, Dena Grayson, Jen L. Salstrom
Journal: Blood
Blood (2024) 144 (Supplement 1): 1825.
https://doi.org/10.1182/blood-2024-203274
Published: 2024
Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Shuhying Tan, Montserrat Arnan, Lynette C.Y. Chee, Thomas Cluzeau, Maria Diez-Campelo, Aristoteles Giagounidis, Devendra Hiwase, David M Ross, Mikkael A. Sekeres, David Valcarcel, Bhavna Patel-Shah, Ming Yang, Ying Jiang, Jiani Yin, Suresh Bobba, Montagu Hankin, Chris Materna, Christine Graham, Sanjay Thamake, Christopher Rovaldi, Dena Grayson, Jen L. Salstrom
Journal: Blood
Blood (2024) 144 (Supplement 1): 4591.
https://doi.org/10.1182/blood-2024-208186
Published: 2024
Journal Articles

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Claire N Harrison, David M. Ross, Lynette C.Y. Chee, Shuhying Tan, Marielle Wondergem, Timothy Devos, Christine Graham, Allie McGinty, Michael Pace, Hongying Wang, Ying Jiang, Suresh Bobba, Katie Louise Dawson, Christopher Rovaldi, Montagu Hankin, Dena Grayson, Simon Cooper, Jen L. Salstrom
Journal: Blood
Blood (2023) 142 (Supplement 1): 3185.
https://doi.org/10.1182/blood-2023-187099
Published: 2023
Journal Articles

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Lynette C.Y. Chee, David M. Ross, Thomas Cluzeau, Shuhying Tan, Aristoteles Giagounidis, David Valcarcel, Montserrat Arnan, Maria Diez-Campelo, Christine Graham, Allie McGinty, Miranda Ross, Suresh Bobba, Wei Feng, Ying Jiang, Montagu Hankin, Christopher Rovaldi, Simon Cooper, Dena Grayson, Jen L. Salstrom
Journal: Blood
Blood (2023) 142 (Supplement 1): 1089.
https://doi.org/10.1182/blood-2023-186326
Published: 2023
Journal Articles

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Maria Diez-Campelo, David M. Ross, Aristoteles Giagounidis, Shuhying Tan, Thomas Cluzeau, Lynette C.Y. Chee, David Valcarcel, Montserrat Arnan, Christine Graham, Allie McGinty, Miranda Ross, Wei Feng, Ying Jiang, Suresh Bobba, Montagu Hankin, Christopher Rovaldi, Dena Grayson, Simon Cooper, Jen L. Salstrom
Journal: Blood
Blood (2023) 142 (Supplement 1): 196.
https://doi.org/10.1182/blood-2023-180974
Published: 2023
Journal Articles

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Alessandro Vannucchi, Srdan Verstovsek, Claire N. Harrison, Prithviraj Bose, Gary J. Schiller, Raajit Rampal, Mark W. Drummond, Vikas Gupta, Andrea Patriarca, Nikki Granacher, Joseph Scandura, Witold Prejzner, Lino L. Teichmann, Natalia Curto-Garcia, Ronald Hoffman, Gozde Colak, Zheng Ren, Suresh Bobba, Jike Cui, Sergey Efuni, Moshe Talpaz
Journal: Blood
Blood (2021) 138 (Supplement 1): 141.
https://doi.org/10.1182/blood-2021-150172
Published: 2021
Journal Articles

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Kristie A. Blum, Jeffrey G. Supko, Michael Maris, Ian W. Flinn, Andre H. Goy, Anas Younes, Suresh Bobba, Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Jeremy S. Abramson
Journal: Blood
Blood (2021) 138 (Supplement 1): 1202.
https://doi.org/10.1182/blood-2021-150852
Published: 2021
Journal Articles

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Katarina Luptakova, MD, Jessica Christo, MA, Jing Wang, PhD, Jennifer A Mertz, PhD, Gozde Colak, PhD, James Shao, MS, Suresh Bobba, MD, Patrick Trojer, PhD, Adrian Senderowicz, MD, Jeffrey S Humphrey, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43.
https://doi.org/10.1182/blood-2020-140901
Published: 2020